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Abstract
Objective. While systemic glucocorticoids compromise bone metabolism, altered intracellular cortisol
availability may also contribute to the pathogenesis of primary male osteoporosis (MO). The objective
of this study was to assess whether intracellular cortisol availability is increased in MO due to a distorted
local cortisol metabolism.
Methods. Forty-one patients with MO were compared with age- and BMI-matched non-osteoporotic
subjects after excluding overt systemic hypercortisolism (N= 41). Cortisol, cortisone and the respective
tetrahydro-, 5a-tetrahydro- and total cortisol metabolites were analysed by GC-MS in 24 h urine. Apparent
11b-hydroxysteroid dehydrogenase (11b-HSD) enzyme activities, excretion of cortisol metabolites and
calcium, and fractional urinary calcium excretion were assessed and related to BMD.
Results. Fractional and total urinary calcium excretion negatively correlated with BMD at all (P< 0.05) and
at three of five (P<0.05) measurement sites, respectively. While systemic cortisol was unchanged, ap-
parent 11b-HSD enzyme activity in MO patients (P<0.01) suggested increased intracellular cortisol avail-
ability. Total and fractional urinary calcium excretion was higher, with apparent 11b-HSD enzyme activities
consistent with an enhanced intracellular cortisol availability (P<0.05).
Conclusion. Apparent 11b-HSD enzyme activities consistent with increased intracellular cortisol availabil-
ity correlated with urinary calcium loss and reduced bone mineral density in MO. The changes in 11b-HSD
activity were associated with both the fractional calcium excretion, suggesting altered renal calcium
handling, and the absolute urinary calcium excretion. Both mechanisms could result in a marked bone
calcium deficiency if insufficiently compensated for by intestinal calcium uptake.
Key words: idiopathic osteoporosis, male, cortisol, 11b-hydroxysteroid dehydrogenase, bone mineral density,
gas chromatographymass spectrometry.
Introduction
Primary male osteoporosis (MO) contributes significantly
to the overall public health burden [1] and is a major
predictor of future fractures and hip fracture-related mor-
bidity and mortality in men [2]. Compared with osteopor-
osis in women, MO is even less recognized and treated in
men, including those with a history of fractures. The diag-
nosis is made after exclusion of secondary causes of
osteoporosis, such as hypogonadism, alcohol abuse,
vitamin D deficiency and use of exogenous glucocortic-
oids [35].
While treatment with exogenous glucocorticoid hor-
mones and endogenous cortisol excess syndromes are
well-known causes of osteoporosis, the contribution of
altered intracellular cortisol (F) availability is less well
defined. Recent work has indicated enhanced F secretion
in subjects with osteoporosis likely due to mild autono-
mous F excess in some individuals [6]. Furthermore,
subclinical hypercortisolism was associated with osteo-
porosis and vertebral fractures in participants referred
for suspected osteoporosis [7]. Likewise, an enhanced
intracellular F may contribute to osteoporosis, an assump-
tion supported by the presence of gene polymorphisms in
11b-hydroxysteroid dehydrogenase type 1 (11b-HSD1), a
primary glucocorticoid regulatory enzyme associated with
low BMD and fracture risk in postmenopausal women
without hypercortisolism [8].
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F binds to both the glucocorticoid and the mineralocor-
ticoid receptor. Intracellular glucocorticoid availability is
effectively controlled on the pre-receptor level by the
enzyme 11b-HSD type 2 (11b-HSD2), catalyzing the deg-
radation of hormonally active F to inactive cortisone (E). In
contrast to 11b-HSD2, the low-affinity enzyme 11b-HSD1,
though bidirectional, predominantly converts E to F as an
oxoreductase and is expressed in human adult bone and
in cultured primary osteoblasts [9, 10].
The enzyme 11b-HSD2 is highly expressed in the kidney
[11], the colon [12] and in fetal bone [13] as well as in
human osteosarcoma cells [10] and at low levels in adult
osteoblasts [9]. Likewise, 11b-HSD1 is the predomin-
ant isozyme expressed in normal adult osteoblasts and
osteoclasts, with both reductase (cortisone-to-cortisol
conversion) and dehydrogenase (cortisol-to-cortisone
conversion) activities [9], and determines their response
to glucocorticoids [14]. In most studies elevated circulat-
ing glucocorticoid concentrations and higher bone turn-
over markers are associated with greater bone loss in
healthy men [1517]. Since bone-specific responses to
glucocorticoids appear to be correlated with serum E
but not F levels [18], the presence of a local activator of
inactive E, i.e. 11b-HSD1, is conceivable. Glucocorticoid
receptor activation is known to directly promote osteopor-
osis, while increased glucocorticoid availability through
inhibition of 11b-HSD2 leads to enhanced urinary calcium
excretion [1922]. Given the availability of the glucocortic-
oid receptor in bone-forming osteoblasts [23], a slightly
dysregulated and thus altered F availability could be caus-
ally related to MO. In line with this reasoning, we hypothe-
sized that integrated 11b-HSD type 1 and type 2 activity is
shifted as a net effect towards higher intracellular F con-
centrations in patients with MO when compared with age-
and BMI-matched non-osteoporotic male subjects.
Material and methods
Study population and study design
Patients were selected from the Department of
Nephrology and Hypertension and from the Department
of Osteoporosis, University Hospital Bern, Bern,
Switzerland. Between 2005 and 2010, more than 3500
male patients were referred for densitometric evaluation
after kidney stone disease or for suspected osteopenia/
osteoporosis or both. Of these, 559 (16%) consecutive
male outpatients underwent further complete bone
metabolic workup due to either renal stone disease and/
or osteopenia/osteoporosis in our department. In this
retrospective casecontrol study, patients with complete
datasets and a diagnosis of MO were included for analysis
and matched for gender, age and BMI (patient allocation
is illustrated in Fig. 1). MO was defined as a fragility frac-
ture or a densitometric T-score 42.5 S.D. at any mea-
sured site (see section on BMD measurements) without
symptoms of overt systemic hypercortisolism and after
exclusion of secondary causes for osteoporosis, such
as a history of or current alcohol abuse, hypogonadism
with low serum testosterone levels (defined as <11 nmol/l
at <60 years, <7 nmol/l at >60 years), primary hyperpara-
thyroidism (pHPT, defined as serum intact PTH 566 ng/l)
and other endocrine disorders, vitamin D deficiency
(defined as serum 25-OH vitamin D <75 nmol/l), hyperthy-
roidism (TSH <0.1 mIU/ml), malabsorption, liver/coeliac
disease, any malignant disease including monoclonal
gammopathy of unknown significance and use of certain
medication or substances (licorice, lithium, anticon-
vulsants, oral anticoagulants, any previous bone
antiresorptive treatment, glucocorticoids, diuretics or
chemotherapy/radiotherapy). Furthermore, patients with
reduced creatinine clearance determined by the modifi-
cation of diet in renal disease (MDRD)-derived
estimated glomerular filtration rate (eGFR) <60 ml/min/
1.73 m2 were excluded. Applying these strict criteria, 41
patients with MO were selected for this casecontrol
study.
Based on the same strict exclusion criteria, 41 non-
osteoporotic patients (CON) with a densitometric
T-score above 2.5 S.D. at all measured sites, referred to
us during the same time period for osteoporosis evalu-
ation and 1:1 matched for BMI and age, were extracted
from the same database and served as control group.
Medical history, radiological records and physical exam-
ination results were available for all patients included.
For the subjects serving as controls, written consent
was obtained according to the Declaration of Helsinki
and was approved by the local institutional review board
of the University of Bern conforming to standards cur-
rently applied in Switzerland. No ethical approval and con-
sent was required for the retrospective analysis of the
patients with overt osteoporosis or fragility fractures. All
individuals with a complete sampled dataset were an-
onymously included in a database. A complete dataset
comprised basic patient demographics, information on
current medication, fracture history and diseases asso-
ciated with osteoporosis. Prospectively collected informa-
tion on vertebral and non-vertebral fractures was
retrospectively analysed after extraction from medical
and radiological records. Body weight and height were
measured on a standard beam scale without shoes and
heavy clothing and using a Harpenden stadiometer as the
average of two consecutive measurements, respectively.
BMI was calculated as kilograms per square metre.
Serum creatinine was used to calculate eGFR. Total
and ionized calcium, phosphate, 25-OH vitamin D, 1,25-
OH2 vitamin D, intact PTH and alkaline phosphatase in
serum samples and creatinine, calcium, sodium and
phosphate in 24 h urine samples were measured using
standard laboratory methods. All urinary measurements
were corrected for urinary creatinine concentrations. The
fractional excretion of calcium (FECa) was calculated as
(urine/serum)calcium/(urine/serum)creatinine.
Urinary steroid hormone analysis by GC-MS
Urinary excretion of steroid hormone metabolites was
determined by GC-MS as reported by Shackleton
and by our group [24, 25]. The 24 h urinary excretion of
tetrahydroaldosterone, F, E, tetrahydro-F (THF), 5a-THF,
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THE and total F metabolites consisting of E, THE, a-
cortolone, b-cortolone, 20a-dihydro-E (20a-DHE),
20b-DHE, F, THF, a-cortol, b-cortol, 20a-DHF, 20b-DHF,
6b-OH-F and 18-OH-F were measured. The apparent
11b-HSD2 and 11b-HSD1 enzyme activity was assessed
by calculating the urinary F/E ratio and the corresponding
ratio of their TH metabolites (THF + 5a-THF)/THE. High
ratios of the apparent activities for urinary F/E and
(THF + 5a-THF)/THE indicate high substrate and low prod-
uct concentrations and reflect low 11b-HSD2 enzyme ac-
tivity. In addition, a high ratio of (THF + 5a-THF)/THE also
indicates a high apparent 11b-HSD1 activity, which acts
as an oxoreductase converting E to F. Excretion of total F
metabolites was determined to obtain a measure for sys-
temic F production and to exclude alterations of the avail-
ability of the substrates used to calculate changes in
enzyme activity as a confounding variable. Ratios for the
excretion of total F metabolites as related to the ratios of
steroid hormone metabolities indicating apparent enzyme
activities were produced to correct for substrate and
product determined variations in enzymatic activities. To
adjust for variations in urine collection, urinary excretion of
steroid hormone metabolites was normalized to micro-
grams of steroid hormone metabolite per millimole of urin-
ary creatinine excretion.
BMD measurements
Routine clinical measurement of BMD was performed at
the lumbar spine (LS), the non-dominant femoral neck
(FN), the proximal femur (PF) and the distal tibial diaphysis
(T-DIA) and epiphysis (T-EPI) using DXA (Hologic QDR
4500A, Hologic, Bedford, MA, USA). Scans were per-
formed according to the manufacturer’s guidelines. The
standardized procedure for tibial measurements was pub-
lished previously by our group [26, 27].
BMD was expressed in grams per square centimetre of
hydroxyapatite and as T-scores (S.D. from the mean of a
healthy young reference population). The National Health
and Nutrition Examination Survey III (NHANES III) data-
base [28, 29] served as reference for all hip sites, and
the manufacturer’s normative database was used as ref-
erence for the LS after analysis according to the
International Society for Clinical Densitometry rules ([30],
official positions 2007; available at http://www.iscd.org/
Visitors/positions/officialPositionsText.cfm). For tibial
BMD, the local Bern normative database served as refer-
ence [31]. Quality control was performed daily (anthropo-
metric spine phantom supplied by the manufacturer) with
an overall precision error of 0.3% in vitro and a mean
precision error in our hands of 1.1% in vivo.
FIG. 1 Patients allocation.
*Patients with one or more of the following exclusion criteria: history of or current alcohol abuse, hypogonadism with low
serum testosterone levels, pHPT and other endocrine disorders (pHPT defined as serum intact PTH566 ng/l), vitamin D
deficiency (defined as serum 25-OH vitamin D <75 nmol/l), hyperthyroidism (defined as TSH <0.1 mIU/ml), malabsorption,
liver/coeliac disease, any malignant disease including monoclonal gammopathy of unknown significance, use of certain
medication or substances (licorice, lithium, anticonvulsants, oral anticoagulants, any previous bone antiresorptive
treatment, glucocorticoids, diuretics or chemotherapy/radiotherapy) and reduced creatinine clearance determined with
eGFR <60 ml/min/1.73 m2.
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Statistical analysis
Data are expressed as means ± S.D. unless otherwise
stated. Normal distribution was assessed by the
D’AgostinoPearson omnibus normality test. First-order
linear regression modelling and correlations as well as a
multivariate linear regression model were chosen to ana-
lyse the relationship between BMD, FECa, ionized serum
calcium, measured steroid hormone metabolites and ap-
parent enzyme activities. 2 testing was used to identify
differences between categorical and dichotomized data.
All analyses were performed using SYSTAT version 12
(SPSS, Inc., Chicago, IL). Significance was assigned at
P< 0.05.
Results
Clinical characteristics of patients
Control subjects and patients were matched for age
(55 ± 2 and 56 ± 3 years, respectively) and BMI (26 ± 1 vs
25 ± 1 kg/m2). The prevalence of diabetes mellitus type II
(5% vs 10%), alcohol abuse (none) and smoking (10% vs
7%) were rare and equally distributed between patients
with and without osteoporosis. Also the combined use of
calcium plus 25-OH vitamin D supplementation (2% vs
2%) was balanced between both groups.
Biochemical parameters
As shown in Table 1, patients with MO did not differ sig-
nificantly from CON with regard to renal function, 25-OH-
and 1,25-(OH)2 vitamin D levels, intact PTH, alkaline phos-
phatase, serum phosphate and total and ionized calcium.
Similar urinary sodium and phosphate excretion in both
groups indicate the absence of substantial nutritional dif-
ferences. However, the FECa (P= 0.0318, Fig. 2A) and ab-
solute urinary excretion of calcium corrected for creatinine
(P= 0.0307, Fig. 2B) were significantly higher in patients
with MO.
Relationship of urinary absolute and fractional
excretion of calcium to BMD
As expected by design, BMD T-scores measured by DXA
were significantly lower at all skeletal sites (LS, FN, PF,
T-DIA and T-EPI) in patients with MO than in the CON
group (Table 1). As direct intestinal calcium uptake and
calcium distribution are difficult to assess, indirect param-
eters such as markers of nutrition, vitamin D and PTH
regulation as well as systemic serum calcium concentra-
tions were applied without obvious major differences be-
tween the two groups.
Significant negative correlations were found between
FECaþþ and BMD at all measurement sites (Fig. 3A; PF
T-score, r2= 0.0535, P= 0.0473; C, FN T-score,
FIG. 2 Urinary calcium loss.
Urinary Ca++ loss in men with primary male osteoporosis (MO, filled square) and nonosteoporotic patients (CON, open
circle). (A) The fractional excretion of Ca++ (FECaþþ , P= 0.0318) and (B) the absolute urinary Ca
++ excretion corrected for
creatinine (P= 0.0307) were higher in patients with MO. Means are specified by the black line. *P< 0.05.
TABLE 1 Biochemical markers
CON MO
Serum
Total calcium, mmol/l 2.35 (0.09) 2.31 (0.09)
Ionized calcium, mmol/l 1.22 (0.03) 1.20 (0.04)
Phosphate, mmol/l 1.02 (0.11) 0.98 (0.16)
Alkaline phosphatase, U/l 74 (57) 71 (21)
Intact PTH, ng/l 40 (12) 42 (13)
25-OH vitamin D, nmol/l 135 (36) 167 (17)
1,25-(OH)2 vitamin D, pmol/l 112 (33) 114 (38)
eGFRMDRD, ml/min/1.73 m
2 89 (13) 91 (18)
24 h urinary
Creatinine, mmol/24 h 14909 (3187) 14490 (4095)
Phosphate, mmol/24 h 33 (11) 30 (10)
Sodium, mmol/24 h 196 (78) 202 (54)
BMD
Lumbar spine (LS) 1.0 (1.1)a 2.5 (1.1)
Proximal femur (PF) 1.1 (0.9)a 1.8 (0.7)
Femoral neck (FN) 0.5 (0.7)b 1.2 (0.8)
Tibial diaphysis (T-DIA) +0.2 (0.9)c 0.5 (1.7)
Tibia epiphysis (T-EPI) 0.9 (0.7)d 1.7 (1.0)
Biochemical markers, mean (S.D.) and BMD of all scan-
ned bone regions as T-scores (S.D. from the mean of a
healthy young reference population) are given. aP< 0.0001.
bP= 0.0001. cP= 0.002. dP= 0.0002.
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FIG. 3 Urinary calcium loss and BMD.
The relation of BMD to FECaþþ (P= 0.0232 between both groups) is shown in (A) the proximal femur (PF; P< 0.0001),
(C) the femoral neck (FN; P< 0.0001), (E) the distal tibial diaphysis (T-DIA; P= 0.0071), (G) the lumbar spine (LS;
P< 0.0001) and (I) distal tibial epiphysis (T-EPI; P= 0.0005) and to absolute urinary Ca++ excretion (P= 0.0307 between
both groups) in (B) PF, (D) FN, (F) T-DIA, (H) LS and (J) T-EPI. CON is indicated by open circles and MO by filled squares.
***P< 0.001, **P< 0.01, *P< 0.05.
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r2= 0.0389, P= 0.0315; E, T-DIA T-score, r2= 0.1306,
P= 0.0020; G, LS T-score, r2 = 0.0956, P= 0.0074; and I,
T-EPI T-score, r2= 0.1337, P= 0.0016) and between urin-
ary Ca++ excretion at some sites (Fig. 3B; PF T-score,
r2= 0.0277, P= NS; D, FN T-score, r2= 0.0180, P= NS; F,
T-DIA T-score, r2 = 0.0535, P= 0.0491; H, LS T-score,
r2= 0.0785, P= 0.0143; and J, T-EPI T-score, r2 = 0.1089,
P= 0.0041).
Mechanisms of increased renal calcium loss: altered
intracellular cortisol availability
Urinary F/E was positively correlated with FECaþþ (Fig. 4A,
r2= 0.0793, P= 0.0125) and with absolute calcium excretion
(Fig. 4B, r2= 0.0522, P= 0.0443), suggesting a renal contri-
bution to the bone calcium deficit. Similar observations were
made for the ratio (THF + 5a-THF)/THE, and although the
degree of correlation was lower, it was statistically signifi-
cant (Fig. 4C; FECaþþ , r
2= 0.0410, P= 0.0449; and D, abso-
lute calcium excretion, r2= 0.0493, P= 0.0478). Systemic
hypercortisolism in patients with MO was excluded by as-
sessing the urinary excretion of total F metabolites, which
did not differ between groups (Fig. 5A). Renal cortisol deg-
radation was compromised in patients with MO, as indicated
by the urinary F/E ratio (Fig. 5B). Similarly, the ratio of
(THF + 5a-THF)/THE suggested enhanced intracellular cor-
tisol availability (Fig. 5C). The difference between the ratio
(F + E)/(THF + 5a-THF + THE) in the two groups indicated
that the renal effect appeared to be prevalent. The
availability of total F metabolites did not affect the apparent
urinary activities F/E (THF + 5a-THF)/THE or (F+ E)/
(THF + 5a-THF + THE) (data not shown).
Discussion
Our study provides first-time evidence that MO is asso-
ciated with enhanced calcium loss via the kidney due to
dysregulation of the 11b-HSD enzyme system, resulting
in enhanced local F availability. We demonstrated a com-
promised F metabolism via the 11b-HSD1 and 11b-HSD2
enzyme systems strongly related to low BMD in patients
with MO, and also that these systems play a role in cal-
cium handling. Taken together, the strong relationship of
BMD and urinary F/E to FECa suggests that a major de-
terminant in renal calcium handling is the renal F metab-
olism via 11b-HSD2. This then controls the availability of F
and its tubular effects on renal calcium balance, such as
provided by the FECa. Given the intracellular location of
the glucocorticoid receptor, systemic hypercortisolism is
not a prerequisite for enhanced receptor activity, which
would also be due to altered intracellular F metabolism.
Bone is a known glucocorticoid target organ. It has
been shown that glucocorticoids increase the lifespan of
osteoclasts, which harbour only 11b-HSD1 [9, 32]. In con-
trast, osteoblast activity is compromised by glucocortic-
oids. These cells are known to host both 11b-HSD1 and
11b-HSD2 [10]. As a result, the glucocorticoid-induced
FIG. 4 Urinary calcium loss was related to apparent enzyme activities of 11b-HSD.
The correlation of FECa to urinary F/E is shown in (A) (r
2 = 0.0740, P= 0.0297), to (THF + 5a-THF)/THE in (C) (r2 = 0.0527,
P= 0.0443), and of absolute urinary Ca++ excretion to urinary F/E in (B) (r2= 0.0623, P= 0.0275) and to (THF + 5a-THF)/
THE in (D) FECa (r
2= 0.0465, P= 0.0498). Cortisol (F), cortisone (E), tetrahydro-F (THF), tetrahydro-E (THE). CON is
indicated by open circles and MO by filled squares. **P< 0.01, *P< 0.05.
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activation of osteoclasts and inactivation of osteoblasts
results in a negative bone calcium balance that ultimately
leads to osteoporosis.
BMD is an established marker of bone health and a
surrogate marker of bone mass that is routinely used for
the clinical assessment of fracture risk. In line with this,
numerous static and dynamic bone histomorphometric
parameter-based studies have demonstrated that hyper-
calciuric patients, e.g. hypercalciuric renal stone-formers,
carry the highest risk of bone disease [31, 3335]. The
effects in our study were not related to systemic gluco-
corticoid availability, but to the integrated apparent
enzyme activity of both 11b-HSDs, which are modulators
of local intracellular F availability. Our findings indicate two
mechanisms related to calcium excretion. First, the
increased cellular F availability releases calcium from the
bone, which leads to enhanced urinary calcium excretion.
Second, the increased intracellular F availability alters
renal calcium handling by promoting FECa, as has been
described in healthy volunteers undergoing inhibition of
11b-HSD2 activity by treatment with glycyrrhetinic acid,
which led to high F availability [36]. This promotes osteo-
porosis by enhanced calcium loss. The calcium loss could
be primarily renal (i.e. a renal calcium leak), resulting in a
negative calcium balance. As the elevated renal FECa is
accompanied by normal serum calcium concentrations,
the enhanced renal loss must be complemented by re-
lease of calcium from enhanced intestinal reabsorption
or bone loss, as manifested in osteoporosis. As hormonal
adaptation by altered vitamin D and/or PTH was not
observed, a role for glucocorticoids appears to be even
more likely.
The ensuing calcium deficiency in the main calcium
storage organ, bone, might be further augmented by
reduced vitamin D stores leading to impaired intestinal
calcium absorption, or by dysregulated calcium distribu-
tion throughout the body. Of note, nutritional indicators,
serum vitamin D, PTH and circulating calcium and
phosphate concentrations were not different between
osteoporosis patients and controls in our study. As this
finding was based on steroid metabolite measurements
in the urine, it is not clear at first glance which
organ system is primarily involved in calcium handling
(i.e. intestine, bone or kidney) and, as such, is responsible
for the osteoporotic state. The alternative scenario of sur-
plus calcium derived from enhanced intestinal calcium
FIG. 5 Intracellular but not systemic F availability was enhanced in MO.
Urinary excretion of total cortisol metabolites (A) was unchanged between CON and patients with MO, whereas
the ratio of (B) urinary F/E (P= 0.0069) and of (C) (THF + 5a-THF)/THE (P= 0.0002) indicated an enhanced intracellular
local F availability in patients with MO. This effect seems to affect the F and E ratio more, indicating renal metabolism of F,
(D) (F + E)/(THF + 5a-THF + THE) (P= 0.0037). Means are specified by the black line. **P< 0.01. NS: not significant.
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absorption excreted by the kidney was not assessed by
our study.
Intestinal calcium uptake is regulated via the activity of
the calcium channel TRPV6. The expression of TRPV6 is
promoted by high 1,25-(OH)2 vitamin D concentrations via
activation of the vitamin D receptor. Glucocorticoids, on
the contrary, impair vitamin D receptor activity and induce
a state of calcium malabsorption. Given the enhanced ac-
tivity of local glucocorticoids seen in our patients with MO,
a primary state of calcium hyperabsorption causing
enhanced renal calcium loss is unlikely. In line with this,
the acute systemic inhibition of 11b-HSD2 by licorice
decreased ionized serum calcium concentrations in
healthy subjects [36].
Among the shortcomings of our study is the lack of
direct measurements of bone 11b-HSD activity.
Furthermore, no standardized dietary protocols were
included to correct for nutritional calcium intake. We
used a cross-sectional design, which shows association
and not causality. Finally, this study was conducted on a
highly selected patient population, and the findings in this
patient population may not be generalizable to the popu-
lation as a whole.
Among the strengths of our study is the homogeneity of
the case and control cohorts. They were of similar age,
came from the same geographic area and had similar
BMIs. We also confirmed bone mineral abnormalities
after strict exclusion of possible secondary causes.
Fragility fractures were assessed and confirmed by radio-
logical methods. Calibrated DXA measurements were per-
formed by a small number of highly qualified and
experienced technicians with high reproducibility. As
renal function was normal in all participants and age
was meticulously matched between both cohorts, deter-
mination of 11b-HSD activity was valid [37, 38].
Furthermore, we excluded major dependencies of the ap-
parent activities as calculated by the ratio of substrate to
product from the availability of total F metabolites.
In conclusion, the alteration in 11b-HSD increases
intracellular F availability. In patients with MO, the over-
all effect is enhanced FECa, suggestive of disturbed
renal calcium handling. Furthermore, the absolute excre-
tion of calcium was more compatible with delivery to
the kidneys from other sources, including enhanced
intestinal reabsorption, increased bone losses, or both,
as present in MO. Enhanced local glucocorticoid avail-
ability is a previously unrecognized risk factor asso-
ciated with osteoporosis. These findings suggest that
novel therapeutic options such as inhibitors of 11b-
HSD1 or activators of 11b-HSD2 might be of benefit
in patients with MO.
Rheumatology key messages
. In primary MO, local glucocorticoid availability is
enhanced due to dysregulated 11b-HSD enzyme
activity.
. In primary MO, enhanced renal calcium loss is
associated with disturbed 11b-HSD activity.
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